Acarbose: Clinical Trials

94 trials of Acarbose, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

65 completed, 17 unknown, 8 terminated, 2 withdrawn. 39 Phase 4, 15 Phase 3, 10 Not applicable, 8 Phase 1, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 439Completed 24, Unknown 11, Terminated 3, Recruiting 1
Phase 315Completed 11, Terminated 2, Unknown 2
Not applicable10Completed 6, Unknown 3, Not yet recruiting 1
Phase 18Completed 8
Phase 27Completed 4, Terminated 2, Withdrawn 1
Early Phase 11Unknown 1

Follow Acarbose: new trials by email Literature Review of Acarbose trials Research Report on Acarbose

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
Acarbose Tablets - Kidney Cancer
Phase 2WithdrawnUniversity of Alabama at Birmingham2025-12-312026-02-17
A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 Diabetes
Cofrogliptin, Acarbose - Type 2 Diabetes
Not applicableNot yet recruitingHaisco Pharmaceutical Group Co., Ltd.2002025-10-012025-09-26
CGM-Guided Acarbose for Painful Diabetic Neuropathy
Acarbose 50 mg, Placebo - Diabetes, Diabetes Complications
Phase 1CompletedShifa International Hospital1702025-09-012026-03-03
Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment
Canagliflozin group, Sitagliptin, Acarbose - Type 2 Diabetes Mellitus, Cognitive Impairment
Phase 4RecruitingFudan University602024-08-192026-07-17
The Efficacy and Tolerability of Acarbose in Healthy Individuals
Acarbose Tablets 50mg - Tolerance, Side Effect
Phase 4CompletedAgelessRx152022-08-102023-07-27
Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes
Metformin plus pioglitazone, Acarbose - Type 2 Diabetes, Blood Glucose Fluctuation
Phase 3UnknownNanjing First Hospital, Nanjing Medical University502022-04-102022-11-29
A Study to Learn More About How Acarbose and Metformin Work When Taken Together and How Safe They Are in Indian Patients Who Were Recently Diagnosed With Type 2 Diabetes (T2D)
BAY81-9783 (Acarbose/Metformin) - Type 2 Diabetes Mellitus
CompletedBayer20002020-12-212024-09-23
Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose
Linagliptin, Acarbose - Diabetes Mellitus, Type 2
TerminatedBoehringer Ingelheim852020-03-042022-06-23
Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents
Glucophage 500Mg Tablet, Acarbose Tablets, Sitagliptin tablet - Type2 Diabetes Mellitus
Phase 4UnknownPeking Union Medical College Hospital1802020-03-022020-02-27
Comparison of the FGM Profiles in Patients of Type 2 Diabetes Treated With Sitagliptin and Acarbose
sitagliptin and acarbose - Type 2 Diabetes
Not applicableCompletedNanjing First Hospital, Nanjing Medical University602020-01-302021-09-05
Bioequivalence Study for Acarbose/Metformin FDC
Acarbose/Metformin FDC(BAY81-9783), Glucobay, Glucophage - Diabetes Mellitus, Type 2
Phase 1CompletedBayer242019-10-142020-04-13
Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive
Alogliptin, Acarbose, Metformin - Type 2 Diabetes Mellitus
Phase 4CompletedSanofi12932019-06-292022-04-25
Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.
Liraglutid, Dapagliflozin, Acarbose - Type 2 Diabetes Mellitus, Obesity
Not applicableUnknownThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School872019-05-012019-05-23
Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
Sitagliptin, Acarbose - Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1
Phase 4UnknownChinese PLA General Hospital3002018-10-012018-07-27
Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus.
Acarbose, Prandial insulin - Gestational Diabetes Mellitus in Pregnancy
Phase 3TerminatedAssistance Publique - Hôpitaux de Paris3412018-07-042024-07-03
Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients
Acarbose, Metformin, Placebo - Diabetes Mellitus, Type 2
Phase 3CompletedBayer2872018-03-052020-08-05
Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy
INSULIN GLARGINE (HOE901), Insulin Glulisine, Biphasic insulin aspart 30 - Type 2 Diabetes Mellitus
Phase 4CompletedSanofi3842018-01-202022-04-25
Research of Intensive Metabolic Intervention Before Pregnancy in PCOS
Acarbose 100 MG, Exenatide, Orlistat - PCOS, Impaired Glucose Tolerance
Phase 4UnknownRenJi Hospital1602018-01-012017-12-26
A Phase IV Study in Drug-Naive Patients With T2DM in China
Dapagliflozin, Acarbose - Type 2 Diabetes Mellitus
Phase 4TerminatedAstraZeneca3042017-12-152021-12-07
Study of Acarbose in Longevity
Acarbose, Placebo - Aging
Phase 2TerminatedMontefiore Medical Center282017-08-302025-06-24

Showing 20 of 94. Sign in to see all of them.

Conditions studied

Diabetes Mellitus, Type 2 (58)  ·  Diabetes Mellitus (22)  ·  Glucose Intolerance (7)  ·  Coronary Artery Disease (3)  ·  Hyperglycemia (3)  ·  Insulin Resistance (3)  ·  Obesity (3)  ·  Cardiovascular Diseases (2)  ·  Cognitive Dysfunction (2)  ·  Coronary Disease (2)  ·  Glucose Metabolism Disorders (2)  ·  Polycystic Ovary Syndrome (2)  ·  Acute Coronary Syndrome (1)  ·  Atherosclerosis (1)  ·  Congenital Hyperinsulinism (1)

Sponsors

Bayer (17)  ·  Canadian Network for Observational Drug Effect Studies, CNODES (3)  ·  Sanofi (3)  ·  Astellas Pharma Inc (2)  ·  AstraZeneca (2)  ·  Boehringer Ingelheim (2)  ·  GWT-TUD GmbH (2)  ·  Merck Sharp & Dohme LLC (2)  ·  Nanjing First Hospital, Nanjing Medical University (2)  ·  Novartis Pharmaceuticals (2)  ·  RenJi Hospital (2)  ·  Taichung Veterans General Hospital (2)  ·  AgelessRx (1)  ·  Aichi Gakuin University (1)  ·  Assistance Publique - Hôpitaux de Paris (1)

Countries

China (29)  ·  United States (11)  ·  Canada (9)  ·  South Korea (8)  ·  Taiwan (6)  ·  Germany (5)  ·  India (5)  ·  Japan (5)  ·  Pakistan (3)  ·  Denmark (2)  ·  Hong Kong (2)  ·  Poland (2)  ·  Algeria (1)  ·  Austria (1)  ·  Bosnia and Herzegovina (1)

Top investigators

Pierre Ernst, MD, MSc (3)  ·  Kenneth M Madden, MD (2)  ·  Tao Tao, MD (2)  ·  Wayne H Sheu, MD, PhD (2)  ·  Ashraf Moini, MD (1)  ·  Bita Eslami, MPH (1)  ·  C.J. Tack, MD, PhD, Prof. of Diabetology (1)  ·  Caroline C Gormsen, M.D. (1)  ·  Dean L Kellogg, Jr, MD, PhD (1)

Results publications

PMID 10662747, PMID 10857967, PMID 11522720, PMID 11904109, PMID 11927799, PMID 12119802, PMID 12832331, PMID 15066944, PMID 15078674, PMID 15710782, PMID 15738343, PMID 16112958, PMID 16681561, PMID 16801564, PMID 16936159, PMID 17515447, PMID 17515448, PMID 17896294, PMID 18539917, PMID 19064853, PMID 19156626, PMID 19515542, PMID 19656312, PMID 19898642, PMID 20061358, PMID 20061360, PMID 20082624, PMID 20215456, PMID 20228401, PMID 20228404, PMID 20427682, PMID 20571135, PMID 20587587, PMID 20594588, PMID 20837887, PMID 20970870, PMID 21366473, PMID 21376417, PMID 21663644, PMID 21813293, PMID 21958949, PMID 22019270, PMID 22049171, PMID 22078152, PMID 22179956, PMID 22311903, PMID 22374637, PMID 22432114, PMID 22450889, PMID 22515638

NIH funding

K23DK074439 (1), N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1), N01HC95183 (1), N01HC95184 (1)